Document is current
Any future updates will be listed below
-
Authors
Harvey-Samuel, Tim https://orcid.org/0000-0003-4006-7034
Feng, Xuechun https://orcid.org/0000-0003-4313-700X
Okamoto, Emily M. https://orcid.org/0009-0004-5682-4719
Purusothaman, Deepak-Kumar https://orcid.org/0000-0003-4827-6519
Leftwich, Philip T. https://orcid.org/0000-0001-9500-6592
Alphey, Luke https://orcid.org/0000-0002-2916-3802
Gantz, Valentino M. https://orcid.org/0000-0003-2453-0711
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NIH Office of the Director (DP5OD023098)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI162911)
- License Information
-
More Information
Article History
Received: 12 June 2023
Accepted: 21 September 2023
First Online: 20 November 2023
Competing interests
: V.M.G. is a founder of and has equity interests in Symbol, Inc. and Agragene, Inc., companies that may potentially benefit from the research results described in this manuscript. V.M.G. also serves on both the company’s Scientific Advisory Board and the Board of Directors of Synbal, Inc. The terms of this arrangement have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. L.A. is an advisor to, and has financial or equity interest in, Synvect Inc. and Biocentis Ltd., companies operating in the area of genetic control of pest insects. X.F., T.H.-S., D.-K.P., P.T.L., and E.M.O. declare no competing interests.
